Cell Biodistribution
Cell Biodistribution - Related Videos
13:29
Biodistribution of Nano-drug Carriers: Applications of SEM
0 Views •
2023
Source: Peiman Shahbeigi-Roodposhti and Sina Shahbazmohamadi, Biomedical Engineering Department, University of Connecticut, Storrs, Connecticut Nanoparticles have been increasingly used research towards targeted drug delivery and controlled drug release. While most of these particles have been developed as polymeric or liposomal particles because of their biocompatibility, there is a trend in current research toward the use of metallic and magnetic nanoparticles. These metallic nanoparticles...
06:15
An In Vivo Immunofluorescence Localization Method to Study Antibody Biodistribution
0 Views •
2025
This video demonstrates an in vivo immunofluorescence localization (IVIL) technique to study the biodistribution of tumor-targeting antibodies in a murine model of breast cancer. Upon the intravenous injection of a tumor-specific antibody in the mouse, the tumor is surgically isolated, and the localization of the antibody within the tumor tissue is confirmed via ex vivo immunostaining.
13:35
Acute and Chronic Models of Hyperglycemia in Zebrafish: A Method to Assess the Impact of Hyperglycemia on Neurogenesis and the Biodistribution of Radiolabeled Molecules
0 Views •
Cited by 28 •
2017
This work describes methods to establish acute and chronic hyperglycemia models in zebrafish. The aim is to investigate the impact of hyperglycemia on physiological processes, such as constitutive and injury-induced neurogenesis. The work also highlights the use of zebrafish to follow radiolabeled molecules (here, [18F]-FDG) using PET/CT.
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
0 Views •
2025
This protocol describes the in vivo reprogramming of mouse cancer cells into type 1 dendritic-like cells within the tumor microenvironment through enforced expression of the transcription factors PU.1, IRF8, and BATF3.
FAQs
Once administered, therapeutic cells are exposed to circulating blood flow and physical tissue barriers that shape where they can move. Adhesion molecules can promote interactions with vessel walls and surrounding tissues, while chemokine signals provide directional cues. Together, these factors influence whether cells leave the circulation, migrate toward particular sites, remain there, or accumulate in unintended organs.
Chemokine signals can guide administered cells toward tissues that produce compatible molecular cues, affecting homing and retention. Immune surveillance adds another control by recognizing and clearing cells from the body. The balance between directional recruitment, tissue residence, and immune-mediated removal helps determine how long cells persist and whether they produce effects at intended or off-target locations.
Persistence indicates how long administered cells remain detectable in the body, whereas clearance reflects their removal over time. These outcomes help researchers interpret whether exposure to a target tissue is sustained or brief. They also inform safety assessment, because prolonged residence or accumulation outside the intended site may increase concern about unwanted tissue effects from regenerative, immune, or gene-modified therapies.
Researchers track administered cells by applying labeling strategies and then examining their distribution with imaging or tissue-based analyses. These approaches can reveal accumulation in intended and unintended tissues, persistence over time, and evidence of clearance. Interpreting the findings requires relating detected cell locations to the administration route, tissue barriers, and biological signals that may have shaped migration.
Administration route determines the initial anatomical environment that cells encounter, while dose changes the number of cells available to circulate, migrate, or accumulate. Biodistribution studies compare these variables to determine whether cells reach the intended target and whether off-target exposure changes. The results can guide delivery-route selection and dose optimization during development of cell-based medicines.
These studies are used when developing regenerative, immune, and gene-modified cell therapies to connect cell location with safety and effectiveness. They help establish whether administered cells reach relevant tissues, identify unexpected accumulation, and evaluate persistence or clearance. Such evidence supports decisions about delivery strategies, dosing, potential tissue effects, and the broader development of cell-based medicines.
Off-target accumulation shows that administered cells have reached tissues beyond the intended therapeutic site. This finding can prompt closer evaluation of unwanted tissue effects and may indicate a need to modify the delivery route or dose. Mapping these locations gives researchers a more complete safety profile than measuring effects only at the target tissue.